ALS Institute Expanding Clinical Locations for Sampling for Biomarker Program | GenomeWeb

NEW YORK (GenomeWeb News) – The ALS Therapy Development Institute, a non-profit that is focused on advancing research into amyotrophic lateral sclerosis, or Lou Gehrig’s disease, said today that it is accelerating its efforts to discover biomarkers that could be used in combating the disease.

The group said it is expanding its effort to collect samples for use in the program, which seeks to identify altered expression of genes and proteins that could be potential biomarkers for diagnosing and monitoring the disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.